IISc-incubated Mynvax to get funding to bring “warm” Covid vaccine to market
The Hindu
The company was developing novel recombinant vaccines for COVID-19 and human influenza and would use the proceeds to further clinical development for the same
Mynvax, a vaccine technology startup, incubated by the Society for Innovation and Development (SID) at the Indian Institute of Science, has signed an agreement to raise $4.2 million (₹31 crore) in its Series A round of financing led by Accel to bring thermotolerant Covid vaccine to the market. The company was developing novel recombinant vaccines for COVID-19 and human influenza and would use the proceeds to further clinical development for the same, it said on Monday. LetsVenture and a few early stage angel investors also participated in this round, which received the backing of its pre-Series A investors such as 1Crowd, Kotak Investment Advisors and other angel investors.More Related News